914647-35-1

Basic information

• Product Name: (E)-3-(2-(4-(trifluoromethyl)benzyl)-1-oxoisoindolin-6-yl)-N-(tetrahydro-2H-pyran-2-yloxy)acrylamide
• Synonyms: (E)-3-(2-(4-(trifluoromethyl)benzyl)-1-oxoisoindolin-6-yl)-N-(tetrahydro-2H-pyran-2-yloxy)acrylamide
• CAS NO: 914647-35-1
• Molecular Weight: 460.453
• Mol File: 914647-35-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (E)-3-(2-(4-(trifluoromethyl)benzyl)-1-oxoisoindolin-6-yl)-N-(tetrahydro-2H-pyran-2-yloxy)acrylamide(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(2-(4-(trifluoromethyl)benzyl)-1-oxoisoindolin-6-yl)-N-(tetrahydro-2H-pyran-2-yloxy)acrylamide(914647-35-1)
• EPA Substance Registry System: (E)-3-(2-(4-(trifluoromethyl)benzyl)-1-oxoisoindolin-6-yl)-N-(tetrahydro-2H-pyran-2-yloxy)acrylamide(914647-35-1)

Safety Data

• Hazardous Substances Data: 914647-35-1(Hazardous Substances Data)

Upstream product

• 18595-12-5 methyl 5-amino-2-methylbenzoate 
• 914646-82-5 (E)-tert-butyl 3-(2-(4-(trifluoromethyl)benzyl)-1-oxoisoindolin-6-yl)acrylate 
• 914646-68-7 methyl 5-(2-(tert-butoxycarbonyl)-2-bromoethyl)-2-methylbenzoate 
• 914646-70-1 methyl 5-(2-(tert-butoxycarbonyl)vinyl)-2-methylbenzoate 
• 914647-08-8 (E)-3-(2-(4-(trifluoromethyl)benzyl)-1-oxoisoindolin-6-yl)acrylic acid 
• 6723-30-4 O-2-tetrahydro-2H-pyranhydroxylamine 
• 914646-72-3 (E)-methyl 5-(2-(tert-butoxycarbonyl)vinyl)-2-bromomethylbenzoate 

Relevant articles and documents

Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors

A series of hydroxamic acid derivatives bearing a cyclic amide/imide group as a linker and/or cap structure, prepared during our structural development studies based on thalidomide, showed class-selective potent histone deacetylase (HDAC)-inhibitory activity. Structure-activity relationship studies indicated that the steric character of the substituent introduced at the cyclic amide/imide nitrogen atom, the presence of the amide/imide carbonyl group, the hydroxamic acid structure, the shape of the linking group, and the distance between the zinc-binding hydroxamic acid group and the cap structure are all important for HDAC-inhibitory activity and class selectivity. A representative compound (30w) showed potent p21 promoter activity, comparable with that of trichostatin A (TSA), and its cytostatic activity against cells of the human prostate cell line LNCaP was more potent than that of the well-known HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA).